Ultragenyx Pharmaceutical Inc. (RARE) financial statements (2022 and earlier)

Company profile

Business Address 60 LEVERONI COURT
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7401,202755460234380437
Cash and cash equivalents30871443411310016194
Short-term investments433488322346134219343
Restricted cash and investments 1100010
Receivables282333135  
Inventory, net of allowances, customer advances and progress billings16131271  
Inventory16131271  
Other undisclosed current assets72475143292013
Total current assets:8571,295851522270402450
Noncurrent Assets
Operating lease, right-of-use asset354130
Property, plant and equipment14174442022177
Long-term investments and receivables259115 1011899
Long-term investments259115 1011899
Intangible assets, net (including goodwill)175176173174186  
Goodwill4444444444  
Intangible assets, net (excluding goodwill)131131129129142  
Restricted cash and investments222 222
Other noncurrent assets21934121
Other undisclosed noncurrent assets3315325    
Total noncurrent assets:666464284197221139109
TOTAL ASSETS:1,5221,7601,135720491541560
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1631219675706028
Accounts payable17131312953
Accrued liabilities1461088362615525
Deferred revenue967 
Debt107    
Deferred revenue and credits100
Other undisclosed current liabilities91     
Total current liabilities:18119010375716028
Noncurrent Liabilities
Long-term debt and lease obligation313930    
Finance lease, liability01 
Operating lease, liability303930
Liabilities, other than long-term debt3433 363661
Deferred tax liabilities, net3131  
Deferred income tax liabilities3333 
Other liabilities1  5561
Other undisclosed noncurrent liabilities353343349    
Total noncurrent liabilities:418416378363661
Total liabilities:6006054821111076728
Stockholders' equity
Stockholders' equity attributable to parent9231,154654609383474531
Common stock0000000
Additional paid in capital2,9972,7732,0871,6401,2221,004817
Accumulated other comprehensive income (loss)(1)1(0)(1)(6)1(1)
Accumulated deficit(2,074)(1,620)(1,433)(1,030)(833)(531)(285)
Total stockholders' equity:9231,154654609383474531
TOTAL LIABILITIES AND EQUITY:1,5221,7601,135720491541560

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues3512711045130 
Revenue, net30 
Cost of revenue
(Cost of Goods and Services Sold)
   (1)(0)  
Gross profit:3512711045030 
Operating expenses(717)(601)(528)(423)(332)(248)(148)
Other undisclosed operating income (loss)(16)  10  
Operating loss:(382)(330)(424)(371)(329)(248)(148)
Nonoperating income081241122
Investment income, nonoperating271310442
Other nonoperating income (expense)(2)1(1)(6)7(2)(0)
Interest and debt expense(0)(0)     
Loss from continuing operations before equity method investments, income taxes:(382)(323)(412)(367)(318)(246)(146)
Other undisclosed income (loss) from continuing operations before income taxes(71)13712170   
Loss from continuing operations before income taxes:(453)(185)(399)(197)(318)(246)(146)
Income tax expense (benefit)(1)(1)(3)(1)16(0) 
Net loss available to common stockholders, diluted:(454)(187)(403)(198)(302)(246)(146)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(454)(187)(403)(198)(302)(246)(146)
Other comprehensive income (loss)(2)105(7)2 
Comprehensive loss:(456)(186)(402)(193)(309)(244)(146)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (1)
Comprehensive loss, net of tax, attributable to parent:(456)(186)(402)(193)(309)(244)(146)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: